Search

Despite advancements in existing antiretroviral-based prevention strategies, including daily oral, locally acting, and injectable options, there is a pressing need for more inclusive and flexible event-driven pre-exposure prophylaxis (PrEP) strategies for all. Event-driven or intermittent dosing of PrEP in populations beyond cisgender men who have sex with men would offer a promising alternative by fitting prevention into the diverse lifestyles of affected populations and thereby advancing health equity. Evidence from PrEP clinical trials, pharmacokinetic studies, modelling studies, and real-world observational research suggests that event-driven PrEP could be a flexible and inclusive option, yet optimal dosing has not been established across sex and gender spectrums. To advance PrEP equity through inclusivity, studies on event-driven PrEP should include people across the gender spectrum. Real-world demonstration studies and simulation studies of optimal dosing strategies are needed. While awaiting further evidence, clinical providers can offer shared decision making and counselling on available data to include event-driven dosing as an option, especially when daily oral, locally acting, or injectable PrEP are not acceptable or preferred methods. Wider access to diverse PrEP options for all populations fosters a more inclusive and effective global HIV prevention strategy., Competing Interests: Declaration of interests WCI reports funding via a ViiV Medical Education Grant and has received honoraria for presentations from Gilead and ViiV. EAB has served as a consultant with Merck for scientific advisory boards and moderating scientific speaking engagements and is principal investigator for a Merck-funded ART treatment study. L-GB has served on advisory boards for ViiV, Gilead, and Merck; has received honoraria for presentations from Merck, Gilead, and ViiV; and has research grants from ViiV and Janssen paid to their institution. J-MM has served on advisory boards for Merck, Gilead, and ViiV and has research grants from Merck and ViiV paid to his institution. MC has received research grants and consulting fees from ViiV, Gilead, and FHI360. MRN has received payment for conference travel and expert testimony from non-pharmaceutical entities. JS declares no competing interests., (Copyright © 2025 Elsevier Ltd. All rights reserved, including those for text and data mining, AI training, and similar technologies.)